|Bid||11.17 x 900|
|Ask||12.25 x 1200|
|Day's range||11.19 - 12.01|
|52-week range||8.02 - 18.68|
|Beta (5Y monthly)||0.02|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2023 - 13 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||27.25|
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CAMBRIDGE, Mass. & MONTREAL, September 19, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced it will present initial data from Module 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial in a plenary session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston, MA. In addition to this presentation, the Company will
CAMBRIDGE, Mass. & MONTREAL, September 06, 2023--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 11:30 a.m. Eastern Time in New York, NY.